In fact, mTOR has presented itself as a valid target for the treatment of RCC, and both everolimus and temsirolimus (first generation of mTOR inhibitors) have EMA- and FDA-approved indications for the treatment of RCC particularly in advanced and/or metastatic RCC patients as well as in patients refractory to anti-VEGF therapy (see Figure 2) [128, 129]. Here, VEGFA is linked to renal cell carcinoma.